Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979060 | 0.85 | MEN1 (0.35) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979046 | 0.85 | KMT2A (0.35) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL14357982 | 0.83 | MEN1 (0.34) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979203 | 0.83 | MEN1 (0.34) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979061 | 0.83 | MEN1 (0.34) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979050 | 0.82 | KMT2A (0.33) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL14476419 | 0.82 | TDP1 (0.35) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979051 | 0.81 | MEN1 (0.33) | CTSKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL14361711 | 0.80 | CTSL (0.32) | MEN1MAPK1KMT2ACTSL | |
| SCHEMBL15979204 | 0.80 | CTSL (0.37) | CTSKMEN1MAPK1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | CTSK 582/4885MEN1 3154/4885MAPK1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.